All In Biotech

Drug Trial Radar · NCT06602024

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 40,805 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

40,805

Actual

Start

Sep 16, 2024

Primary completion

Aug 21, 2025

Study completion Aug 21, 2025

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.

Conditions

  • Seasonal Influenza

Interventions

  • mRNA-1010Biological

    Intramuscular (IM) injection

  • Fluarix®Biological

    IM injection

  • Influsplit® TetraBiological

    IM injection

  • Fluarix TetraBiological

    IM injection

  • Alpharix® TetraBiological

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Day 1 up to Day 7
  2. Number of Participants With Unsolicited Adverse Events (AEs)Time frame: Day 1 up to Day 28
  3. Number of Participants With Medically Attended AEs (MAAEs), AEs Leading to Study Discontinuation, SAEs, or Adverse Events of Special Interests (AESIs)Time frame: Day 1 up to Day 181
  4. Number of Participants With First Episode of Reverse Tanscription Polymerase Chain Reaction (RT-PCR) Confirmed Protocol Defined Influenza-like Illness (ILI) Caused by Any Influenza A or B StrainsTime frame: Day 14 up to end of influenza season (up to 7.5 months)

Locations

301 sites in 11 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group, Llc

    Anniston, Alabama

  • North Alabama Research Center, LLC

    Athens, Alabama

  • Flourish Research

    Birmingham, Alabama

  • EmVenio Research Brimingham, AL

    Birmingham, Alabama

  • Cullman Clinical Trials

    Cullman, Alabama

  • Optimal Research

    Huntsville, Alabama

  • Velocity Clinical Research

    Mobile, Alabama

  • Lenzmeier Family Medicine

    Glendale, Arizona

  • DM Clinical Research

    Phoenix, Arizona

  • Helios Clinical Research

    Phoenix, Arizona

  • Fiel Family and Sports Medicine

    Tempe, Arizona

  • Arizona Liver Health

    Tucson, Arizona

  • Baptist Health Center for Clinical Research

    Little Rock, Arkansas

  • Woodland Research

    Rogers, Arkansas

  • Benchmark Research - Colton

    Colton, California

  • Flourish Research

    Covina, California

  • Velocity Clinical Research - Huntington Park

    Huntington Park, California

  • Velocity Clinical Research, San Diego

    La Mesa, California

  • Long Beach Research Institute LLC

    Long Beach, California

  • Velocity Clinical Research - Westlake

    Los Angeles, California

  • M3 Wake Research/PRI, LLC

    Newport Beach, California

  • Carbon Health North Hollywood

    North Hollywood, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Paradigm Research

    Redding, California

  • Artemis Institute for Clinical Research

    Riverside, California

  • Peninsula Research Associates (PRA)

    Rolling Hills Estates, California

  • Velocity Clinical Research - Banning

    San Bernardino, California

  • Artemis Institute for Clinical Research - Research Site

    San Diego, California

  • WHCR- M3 Wake Research

    San Diego, California

  • Wr-McCr, Llc

    San Diego, California

  • Velocity Clinical Research

    Santa Ana, California

  • Diablo Clinical Research

    Walnut Creek, California

  • Tekton Research - Fort Collins

    Fort Collins, Colorado

  • Tekton Research, Inc - Longmont Center

    Longmont, Colorado

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • JEM Research Institue

    Atlantis, Florida

  • Nature Coast Clinical Research, LLC - Crystal River

    Crystal River, Florida

  • Homestead Associates in Research,Inc

    Hialeah, Florida

  • CenExel RCA

    Hollywood, Florida

Showing 40 of 301 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.